Cargando…

Vaccination information, motivations, and barriers in the context of meningococcal serogroup A conjugate vaccine introduction: A qualitative assessment among caregivers in Burkina Faso, 2018

BACKGROUND: In March 2017, Burkina Faso introduced meningococcal serogroup A conjugate vaccine (MACV) into the Expanded Programme on Immunization. MACV is administered to children aged 15–18 months, concomitantly with the second dose of measles-containing vaccine (MCV2). One year after MACV introduc...

Descripción completa

Detalles Bibliográficos
Autores principales: Aksnes, Brooke Noel, Walldorf, Jenny A., Nkwenkeu, Sylvain F., Zoma, Robert L., Mirza, Imran, Tarbangdo, Felix, Fall, Soukeynatou, Hien, Sansan, Ky, Cesaire, Kambou, Ludovic, Diallo, Alpha Oumar, Aké, Flavien H., Hatcher, Cynthia, Patel, Jaymin C., Novak, Ryan T., Hyde, Terri B., Medah, Isaïe, Soeters, Heidi M., Jalloh, Mohamed F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8519392/
https://www.ncbi.nlm.nih.gov/pubmed/34579975
http://dx.doi.org/10.1016/j.vaccine.2021.09.038
_version_ 1784584439201792000
author Aksnes, Brooke Noel
Walldorf, Jenny A.
Nkwenkeu, Sylvain F.
Zoma, Robert L.
Mirza, Imran
Tarbangdo, Felix
Fall, Soukeynatou
Hien, Sansan
Ky, Cesaire
Kambou, Ludovic
Diallo, Alpha Oumar
Aké, Flavien H.
Hatcher, Cynthia
Patel, Jaymin C.
Novak, Ryan T.
Hyde, Terri B.
Medah, Isaïe
Soeters, Heidi M.
Jalloh, Mohamed F.
author_facet Aksnes, Brooke Noel
Walldorf, Jenny A.
Nkwenkeu, Sylvain F.
Zoma, Robert L.
Mirza, Imran
Tarbangdo, Felix
Fall, Soukeynatou
Hien, Sansan
Ky, Cesaire
Kambou, Ludovic
Diallo, Alpha Oumar
Aké, Flavien H.
Hatcher, Cynthia
Patel, Jaymin C.
Novak, Ryan T.
Hyde, Terri B.
Medah, Isaïe
Soeters, Heidi M.
Jalloh, Mohamed F.
author_sort Aksnes, Brooke Noel
collection PubMed
description BACKGROUND: In March 2017, Burkina Faso introduced meningococcal serogroup A conjugate vaccine (MACV) into the Expanded Programme on Immunization. MACV is administered to children aged 15–18 months, concomitantly with the second dose of measles-containing vaccine (MCV2). One year after MACV introduction, we assessed the sources and content of immunization information available to caregivers and explored motivations and barriers that influence their decision to seek MACV for their children. METHODS: Twenty-four focus group discussions (FGDs) were conducted with caregivers of children eligible for MACV and MCV2. Data collection occurred in February–March 2018 in four purposively selected districts, each from a separate geographic region; within each district, caregivers were stratified into groups based on whether their children were unvaccinated or vaccinated with MACV. FGDs were recorded and transcribed. Transcripts were coded and analyzed using qualitative content analysis. RESULTS: We identified many different sources and content of information about MACV and MCV2 available to caregivers. Healthcare workers were most commonly cited as the main sources of information; caregivers also received information from other caregivers in the community. Caregivers’ motivations to seek MACV for their children were driven by personal awareness, engagements with trusted messengers, and perceived protective benefits of MACV against meningitis. Barriers to MACV and MCV2 uptake were linked to the unavailability of vaccines, immunization personnel not providing doses, knowledge gaps about the 15–18 month visit, practical constraints, past negative experiences, sociocultural influences, and misinformation, including misunderstanding about the need for MCV2. CONCLUSIONS: MACV and MCV2 uptake may be enhanced by addressing vaccination barriers and effectively communicating vaccination information and benefits through trusted messengers such as healthcare workers and other caregivers in the community. Educating healthcare workers to avoid withholding vaccines, likely due to fear of wastage, may help reduce missed opportunities for vaccination.
format Online
Article
Text
id pubmed-8519392
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier Science
record_format MEDLINE/PubMed
spelling pubmed-85193922021-10-21 Vaccination information, motivations, and barriers in the context of meningococcal serogroup A conjugate vaccine introduction: A qualitative assessment among caregivers in Burkina Faso, 2018 Aksnes, Brooke Noel Walldorf, Jenny A. Nkwenkeu, Sylvain F. Zoma, Robert L. Mirza, Imran Tarbangdo, Felix Fall, Soukeynatou Hien, Sansan Ky, Cesaire Kambou, Ludovic Diallo, Alpha Oumar Aké, Flavien H. Hatcher, Cynthia Patel, Jaymin C. Novak, Ryan T. Hyde, Terri B. Medah, Isaïe Soeters, Heidi M. Jalloh, Mohamed F. Vaccine Article BACKGROUND: In March 2017, Burkina Faso introduced meningococcal serogroup A conjugate vaccine (MACV) into the Expanded Programme on Immunization. MACV is administered to children aged 15–18 months, concomitantly with the second dose of measles-containing vaccine (MCV2). One year after MACV introduction, we assessed the sources and content of immunization information available to caregivers and explored motivations and barriers that influence their decision to seek MACV for their children. METHODS: Twenty-four focus group discussions (FGDs) were conducted with caregivers of children eligible for MACV and MCV2. Data collection occurred in February–March 2018 in four purposively selected districts, each from a separate geographic region; within each district, caregivers were stratified into groups based on whether their children were unvaccinated or vaccinated with MACV. FGDs were recorded and transcribed. Transcripts were coded and analyzed using qualitative content analysis. RESULTS: We identified many different sources and content of information about MACV and MCV2 available to caregivers. Healthcare workers were most commonly cited as the main sources of information; caregivers also received information from other caregivers in the community. Caregivers’ motivations to seek MACV for their children were driven by personal awareness, engagements with trusted messengers, and perceived protective benefits of MACV against meningitis. Barriers to MACV and MCV2 uptake were linked to the unavailability of vaccines, immunization personnel not providing doses, knowledge gaps about the 15–18 month visit, practical constraints, past negative experiences, sociocultural influences, and misinformation, including misunderstanding about the need for MCV2. CONCLUSIONS: MACV and MCV2 uptake may be enhanced by addressing vaccination barriers and effectively communicating vaccination information and benefits through trusted messengers such as healthcare workers and other caregivers in the community. Educating healthcare workers to avoid withholding vaccines, likely due to fear of wastage, may help reduce missed opportunities for vaccination. Elsevier Science 2021-10-15 /pmc/articles/PMC8519392/ /pubmed/34579975 http://dx.doi.org/10.1016/j.vaccine.2021.09.038 Text en https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Aksnes, Brooke Noel
Walldorf, Jenny A.
Nkwenkeu, Sylvain F.
Zoma, Robert L.
Mirza, Imran
Tarbangdo, Felix
Fall, Soukeynatou
Hien, Sansan
Ky, Cesaire
Kambou, Ludovic
Diallo, Alpha Oumar
Aké, Flavien H.
Hatcher, Cynthia
Patel, Jaymin C.
Novak, Ryan T.
Hyde, Terri B.
Medah, Isaïe
Soeters, Heidi M.
Jalloh, Mohamed F.
Vaccination information, motivations, and barriers in the context of meningococcal serogroup A conjugate vaccine introduction: A qualitative assessment among caregivers in Burkina Faso, 2018
title Vaccination information, motivations, and barriers in the context of meningococcal serogroup A conjugate vaccine introduction: A qualitative assessment among caregivers in Burkina Faso, 2018
title_full Vaccination information, motivations, and barriers in the context of meningococcal serogroup A conjugate vaccine introduction: A qualitative assessment among caregivers in Burkina Faso, 2018
title_fullStr Vaccination information, motivations, and barriers in the context of meningococcal serogroup A conjugate vaccine introduction: A qualitative assessment among caregivers in Burkina Faso, 2018
title_full_unstemmed Vaccination information, motivations, and barriers in the context of meningococcal serogroup A conjugate vaccine introduction: A qualitative assessment among caregivers in Burkina Faso, 2018
title_short Vaccination information, motivations, and barriers in the context of meningococcal serogroup A conjugate vaccine introduction: A qualitative assessment among caregivers in Burkina Faso, 2018
title_sort vaccination information, motivations, and barriers in the context of meningococcal serogroup a conjugate vaccine introduction: a qualitative assessment among caregivers in burkina faso, 2018
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8519392/
https://www.ncbi.nlm.nih.gov/pubmed/34579975
http://dx.doi.org/10.1016/j.vaccine.2021.09.038
work_keys_str_mv AT aksnesbrookenoel vaccinationinformationmotivationsandbarriersinthecontextofmeningococcalserogroupaconjugatevaccineintroductionaqualitativeassessmentamongcaregiversinburkinafaso2018
AT walldorfjennya vaccinationinformationmotivationsandbarriersinthecontextofmeningococcalserogroupaconjugatevaccineintroductionaqualitativeassessmentamongcaregiversinburkinafaso2018
AT nkwenkeusylvainf vaccinationinformationmotivationsandbarriersinthecontextofmeningococcalserogroupaconjugatevaccineintroductionaqualitativeassessmentamongcaregiversinburkinafaso2018
AT zomarobertl vaccinationinformationmotivationsandbarriersinthecontextofmeningococcalserogroupaconjugatevaccineintroductionaqualitativeassessmentamongcaregiversinburkinafaso2018
AT mirzaimran vaccinationinformationmotivationsandbarriersinthecontextofmeningococcalserogroupaconjugatevaccineintroductionaqualitativeassessmentamongcaregiversinburkinafaso2018
AT tarbangdofelix vaccinationinformationmotivationsandbarriersinthecontextofmeningococcalserogroupaconjugatevaccineintroductionaqualitativeassessmentamongcaregiversinburkinafaso2018
AT fallsoukeynatou vaccinationinformationmotivationsandbarriersinthecontextofmeningococcalserogroupaconjugatevaccineintroductionaqualitativeassessmentamongcaregiversinburkinafaso2018
AT hiensansan vaccinationinformationmotivationsandbarriersinthecontextofmeningococcalserogroupaconjugatevaccineintroductionaqualitativeassessmentamongcaregiversinburkinafaso2018
AT kycesaire vaccinationinformationmotivationsandbarriersinthecontextofmeningococcalserogroupaconjugatevaccineintroductionaqualitativeassessmentamongcaregiversinburkinafaso2018
AT kambouludovic vaccinationinformationmotivationsandbarriersinthecontextofmeningococcalserogroupaconjugatevaccineintroductionaqualitativeassessmentamongcaregiversinburkinafaso2018
AT dialloalphaoumar vaccinationinformationmotivationsandbarriersinthecontextofmeningococcalserogroupaconjugatevaccineintroductionaqualitativeassessmentamongcaregiversinburkinafaso2018
AT akeflavienh vaccinationinformationmotivationsandbarriersinthecontextofmeningococcalserogroupaconjugatevaccineintroductionaqualitativeassessmentamongcaregiversinburkinafaso2018
AT hatchercynthia vaccinationinformationmotivationsandbarriersinthecontextofmeningococcalserogroupaconjugatevaccineintroductionaqualitativeassessmentamongcaregiversinburkinafaso2018
AT pateljayminc vaccinationinformationmotivationsandbarriersinthecontextofmeningococcalserogroupaconjugatevaccineintroductionaqualitativeassessmentamongcaregiversinburkinafaso2018
AT novakryant vaccinationinformationmotivationsandbarriersinthecontextofmeningococcalserogroupaconjugatevaccineintroductionaqualitativeassessmentamongcaregiversinburkinafaso2018
AT hydeterrib vaccinationinformationmotivationsandbarriersinthecontextofmeningococcalserogroupaconjugatevaccineintroductionaqualitativeassessmentamongcaregiversinburkinafaso2018
AT medahisaie vaccinationinformationmotivationsandbarriersinthecontextofmeningococcalserogroupaconjugatevaccineintroductionaqualitativeassessmentamongcaregiversinburkinafaso2018
AT soetersheidim vaccinationinformationmotivationsandbarriersinthecontextofmeningococcalserogroupaconjugatevaccineintroductionaqualitativeassessmentamongcaregiversinburkinafaso2018
AT jallohmohamedf vaccinationinformationmotivationsandbarriersinthecontextofmeningococcalserogroupaconjugatevaccineintroductionaqualitativeassessmentamongcaregiversinburkinafaso2018